The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

Intraoperative floppy iris syndrome is associated with an increased rate of severe intraoperative complications and greater ...

Investigators advised clinicians of the potential for dystrophies that mimic age-related macular degeneration and other ...

The combined companies will operate under the name Kalaris Therapeutics, Inc. and expects to report initial data from part 1 ...

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with ...

A retrospective study showed that the gender of the ophthalmologist influenced the amount of communication with the patient, ...

Ambulatory surgical centers are freestanding health care facilities that specialize in providing surgical and diagnostic ...

The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...

ZEISS VISULAS Combi is an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp ...

This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price ...

The treatment was approved by China’s National Medical Products Administration (NMPA) and is China's first, and the world’s ...